Bifogade filer
Annual Report 2023 04 15 Final 4
mendusab-2023-12-31-sv_preview
Kurs
-0,20%
Likviditet
1,18 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-05-09 | - | Årsstämma |
| 2025-02-13 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-08 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-03 | - | Split IMMU 20:1 |
| 2024-05-20 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2024-05-17 | - | Årsstämma |
| 2024-05-17 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-12-13 | - | Extra Bolagsstämma 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-29 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-15 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2023-05-12 | - | Årsstämma |
| 2023-05-12 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Extra Bolagsstämma 2022 |
| 2022-11-11 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2022-05-10 | - | Årsstämma |
| 2022-05-10 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2021-05-04 | - | Årsstämma |
| 2021-05-04 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2021-01-22 | - | Extra Bolagsstämma 2021 |
| 2020-12-18 | - | Extra Bolagsstämma 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-29 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2020-04-28 | - | Årsstämma |
| 2020-04-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-18 | - | Bokslutskommuniké 2019 |
| 2019-11-06 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-20 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2019-04-25 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-15 | - | Bokslutskommuniké 2018 |
| 2018-11-07 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-17 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-04 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-26 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2018-04-25 | - | Årsstämma |
| 2018-02-16 | - | Bokslutskommuniké 2017 |
| 2017-12-04 | - | Extra Bolagsstämma 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-19 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-27 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2017-04-26 | - | Årsstämma |
| 2017-02-17 | - | Bokslutskommuniké 2016 |
| 2016-05-20 | - | Kvartalsrapport 2016-Q3 |
| 2016-02-19 | - | Kvartalsrapport 2016-Q2 |
| 2015-12-03 | - | Årsstämma |
| 2015-09-18 | - | Bokslutskommuniké 2015 |
| 2015-05-21 | - | Kvartalsrapport 2015-Q3 |
| 2015-02-20 | - | Kvartalsrapport 2015-Q2 |
| 2014-12-04 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2014-12-03 | - | Årsstämma |
| 2014-11-18 | - | Kvartalsrapport 2015-Q1 |
| 2014-09-17 | - | Bokslutskommuniké 2014 |
| 2014-05-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-02-18 | - | Kvartalsrapport 2014-Q2 |
| 2013-12-04 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2013-12-03 | - | Årsstämma |
| 2013-12-03 | - | Kvartalsrapport 2014-Q1 |
| 2013-09-10 | - | Bokslutskommuniké 2013 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Press release
Stockholm, Sweden, April 17, 2024
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that the Annual Report for 2023 has been published. The Annual Report is attached as a PDF and is available on the company’s corporate website: https://mendus.com/investors/financial-reports/
Mendus’ shareholders can request a printed copy of the Annual Report by contacting the company by e-mail, ir@mendus.com.
For more information, please contact:
Erik Manting, CEO
E-mail: ir@mendus.com
About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/
This information is information that Mendus is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-17 22:05 CEST.